Stock Upgrades Today See Wall Street Boost Confidence

 TopRated
 
  TopRated
 
Follow  Message
 
 
 
TopRatedStocks uncovering top-rated companies. Providing quick insights and recommendations, they help investors discover high-potential stocks based on robust metrics.
 

•  21 Nov 2025
 

•   ACM  
   
  +0.17%
•   ADBE  
   
  +0.04%
•   AMD  
   
  +0.10%
•   APO  
   
  +0.08%
•   ASMB  
   
  +0.71%

$ACM continues to attract investor attention as RBC Capital and Argus Research maintain their Outperform and Buy recommendations, projecting a potential upside of 37.68%. The strong backlog of infrastructure projects and exposure to high-growth engineering markets underpin analyst confidence. With robust revenue visibility and solid execution on large-scale contracts, ACM remains positioned to capture demand in both public and private sector projects, making it a compelling choice for long-term investors.

$ADBE sees sustained optimism with DA Davidson and Mizuho reaffirming Buy and Outperform ratings, suggesting a striking upside of nearly 51%. Adobe leadership in creative and digital experience software, coupled with recurring subscription revenue, strengthens its financial resilience. Analysts point to continued margin expansion and global adoption of AI-powered tools as key growth drivers, highlighting the potential for sustained momentum.

$AMD is drawing bullish attention as analysts highlight its trajectory toward a trillion-dollar market cap. The upgrade to Buy reflects confidence in AMD CPU and GPU market share gains, strategic partnerships, and expanding data center footprint. Strong margins and robust demand for high-performance computing solutions continue to fuel investor enthusiasm, suggesting the growth story is far from mature.

$APO has received an upgrade from Morgan Stanley to Overweight, projecting upside of nearly 28%. Apollo Global Management benefits from a diversified alternative investment platform, capitalizing on favorable credit market conditions and private equity exits. The upgrade underscores confidence in Apollo ability to deploy capital efficiently while delivering strong risk-adjusted returns for investors.

$ASMB maintains momentum with Mizuho reaffirming an Outperform rating and a modest upside of 6.14%. Assembly Biosciences’ focus on innovative antiviral therapies supports long-term growth, though near-term upside remains limited compared to higher-volatility peers in biotech.

$AXP has been upgraded to Buy by multiple analysts, reflecting renewed confidence in American Express’ earnings trajectory. Strong credit card spending trends, a resilient consumer base, and higher fee income contribute to an expected near-term upside, while the stock benefits from stable credit quality and strategic global positioning.

$BBWI is favored by Telsey Advisory and B of A Securities, both highlighting an impressive 133% potential upside. Bath & Body Works continues to capitalize on brand loyalty, seasonal product cycles, and e-commerce expansion, signaling a significant opportunity for investors seeking retail growth stories.

$BCC maintains its Buy rating with DA Davidson projecting upside of 33.73%. Boise Cascade positioning in building materials and strong demand for construction products underpin its attractiveness, reflecting broader residential and commercial construction trends.

$BILI has been upgraded to Buy, signaling optimism over the Chinese online entertainment market. Analysts point to strong content monetization and user engagement as key drivers, though regulatory risks remain a consideration.

$BKR continues to hold a Buy rating with modest upside, reflecting steady performance in oilfield services and benefits from an improving energy sector.

$BLSH shows promise with a 69% upside forecast, supported by Rosenblatt Buy recommendation. Investors are drawn to the potential in high-growth markets, though volatility may remain elevated.

$BSX has been upgraded to Buy with positive expectations driven by expanding medical device demand and strong pipeline execution, signaling upside potential for healthcare-focused investors.

$CNP sees optimism with a Buy rating, supported by improving utility earnings and strategic investments in sustainable infrastructure.

$CNXC retains an Outperform rating with near-term upside of 98%, driven by growth in outsourced customer experience and technology services.

$CWAN remains a favored mid-cap stock with a Buy rating amid takeover interest and strong hedge fund support, reflecting confidence in the strategic positioning and potential acquisition premium.

$CWK is supported by a Buy upgrade at Citi, expected to benefit from increased leasing activity and a recovering commercial real estate sector.

$DNN maintains a Buy rating with potential upside, reflecting gains in uranium production and strong commodity market positioning.

$DOCS sees growth optimism following Raymond James upgrade, highlighting increasing visibility in digital healthcare communications.

$DSGN upgraded to Outperform by RBC Capital, reflecting promising early-stage pipeline developments and potential near-term catalysts in therapeutics.

$DY maintains its Buy rating despite slight downside expectations, reflecting steady demand in telecom infrastructure and reliable contract visibility.

$ECC and $EIC maintain Buy ratings with strong upside potential in specialty credit and income strategies, appealing to yield-focused investors.

$EKSO upgraded to Buy, reflecting optimism around robotics adoption in healthcare and industrial sectors, with clear near-term growth catalysts.

$ESI retains an Outperform rating with significant upside, underpinned by specialty chemicals and industrial applications.

$ETR benefits from forward-looking investments in energy infrastructure, nuclear expansion, and grid modernization, supporting a bullish view on strategic positioning.

$FLUT maintains a Buy rating, reflecting momentum in online sports betting and gaming expansion.

$FUTU upgraded at Citi, reflecting improving Q4 prospects and fintech adoption trends.

View All Headlines